Table 2.

Representative prospective clinical trials on thrombolytic therapy in post-cardiac arrest syndrome.

Authors	Design	Subject	Thrombolytic drug	Outcome	Hemorrhagic complication
Böttiger et al. (91)	Prospective observational trial	OHCA	t-PA	ROSC: 68 vs 44% (p = 0.026)	2 patients with thrombolytic required transfusion vs 0 with control (p = 0.379)
				Admission to cardiac ICU: 58 vs 30% (p = 0.009)
				Survival up to 24 h: 35 vs 22% (p = 0.171)
				Survival till discharge: 15 vs 8% (no p value provided)
				All above are thrombolytic group vs control group
Abu-Laban et al. (92)	Prospective, randomized, placebo-controlled trial	PEA unresponsive to initial therapy	t-PA	No significant difference in outcome, including ROSC, length of hospital stay, and survival to hospital discharge	2 major hemorrhage with thrombolytic vs 1 major and 1 minor hemorrhage with control (p = 0.50 and p = 0.99, respectively)
Böttiger et al. (97)	Prospective, randomized, placebo-controlled trial	Witnessed OHCA due to presumed cardiac causes	Tenecteplase	No significant differences in 30-day survival, hospital admission, ROSC, 24-h survival, survival to hospital discharge, or neurologic outcome	Intracranial hemorrhage: 2.7% with thrombolytics vs 0.4% with control (p = 0.006)

OHCA, out-of-hospital cardiac arrest; PEA, pulseless electrical activity; t-PA, tissue-type plasminogen activator; ROSC, return of spontaneous circulation.